Mineralys Therapeutics, Inc.
MLYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $886 | $844 | $615 |
| - Cash | $218 | $102 | $165 | $114 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $784 | $679 | $501 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$37 | -$47 | -$44 | -$52 |
| % Margin | – | – | – | – |
| Net Income | -$37 | -$43 | -$42 | -$49 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.52 | -0.66 | -0.79 | -0.98 |
| % Growth | 21.2% | 16.5% | 19.4% | – |
| Operating Cash Flow | -$29 | -$30 | -$45 | -$67 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$29 | -$30 | -$45 | -$67 |